查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
失智症·阿兹海默症治疗的全球市场 - 产业规模，占有率，趋势，机会，预测(2018年～2028年)各级药品，各流通管道，各地区，预测，机会(2028年)
市场调查报告书
商品编码
1174496

失智症·阿兹海默症治疗的全球市场 - 产业规模，占有率，趋势，机会，预测(2018年～2028年)各级药品，各流通管道，各地区，预测，机会(2028年)

Dementia and Alzheimer's Disease Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Distribution Channel, By Region, Forecast & Opportunities, 2028
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球失智症·阿兹海默症治疗市场在2024年～2028年的预测期间内将展现惊人成长。

阿尔茨海默病和痴呆症患病率的增加以及对这些疾病的认识不断提高正在推动市场的增长。

本报告提供全球失智症·阿兹海默症治疗市场相关调查分析，提供市场规模与预测，各地区预测，竞争情形等资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 摘要整理

第4章 VOC (客户的迴响)

第5章 临床试验分析

  • 进行中的临床试验
  • 达成的临床试验
  • 结束的临床试验
  • 开发平台(管线)的明细:各开发阶段
  • 开发平台(管线)的明细:各状态
  • 开发平台(管线)的明细:各研究类型
  • 开发平台(管线)的明细:各国
  • 临床试验热图

第6章 全球失智症·阿兹海默症治疗市场预测

  • 市场规模与预测
  • 市场占有率与预测
    • 各级药品(胆碱工作性/胆碱酯酶(ChE)抑制剂(Donepezil，galantamine，Rivastigmine)，Memantine，并用药(Memantine·Donepezil))
    • 各流通管道(医院药局，零售药局，线上药局)
    • 各企业(2022年)
    • 各地区
  • 市场魅力指数

第7章 亚太地区的失智症·阿兹海默症治疗市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 亚太地区:各国分析
    • 中国的失智症·阿兹海默症治疗市场预测
    • 印度的失智症·阿兹海默症治疗市场预测
    • 澳洲的失智症·阿兹海默症治疗市场预测
    • 日本的失智症·阿兹海默症治疗市场预测
    • 韩国的失智症·阿兹海默症治疗市场预测

第8章 欧洲的失智症·阿兹海默症治疗市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 欧洲:各国分析
    • 法国的失智症·阿兹海默症治疗市场预测
    • 德国的失智症·阿兹海默症治疗市场预测
    • 英国的失智症·阿兹海默症治疗市场预测
    • 义大利的失智症·阿兹海默症治疗市场预测
    • 西班牙的失智症·阿兹海默症治疗市场预测

第9章 北美的失智症·阿兹海默症治疗市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 北美:各国分析
    • 美国的失智症·阿兹海默症治疗市场预测
    • 墨西哥的失智症·阿兹海默症治疗市场预测
    • 加拿大幅失智症·阿兹海默症治疗市场预测

第10章 南美的失智症·阿兹海默症治疗市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 南美:各国分析
    • 巴西的失智症·阿兹海默症治疗市场预测
    • 阿根廷的失智症·阿兹海默症治疗市场预测
    • 哥伦比亚的失智症·阿兹海默症治疗市场预测

第11章 中东·非洲的失智症·阿兹海默症治疗市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 中东·非洲:各国分析
    • 南非的失智症·阿兹海默症治疗市场预测
    • 沙乌地阿拉伯的失智症·阿兹海默症治疗市场预测
    • 阿拉伯联合大公国的失智症·阿兹海默症治疗市场预测

第12章 市场动态

  • 促进因素
  • 课题

第13章 市场趋势与发展

第14章 竞争情形

  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Corium, Inc.

第15章 策略性建议

简介目录
Product Code: 5058

Global dementia and Alzheimer's disease treatment market is expected to grow at impressive growth during the forecast period, 2024-2028. The increasing cases of Alzheimer's and dementia coupled with growing awareness regarding the diseases are bolstering the growth of the market. Moreover, elderly population are more prone to such diseases due to growing age, which in turn, is expected to positively impact the growth of market. Also, upsurge in R&D activities associated with disease, the introduction of new and innovative technologies and drugs, and increasing government initiatives such as investments, awareness programmes are expected to bolster the growth of market over the next few years. For instance, in 2022, a new initiative by McGill University's Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities.

The global dementia and Alzheimer's disease treatment market is segmented into drug class, distribution channel, company and region. Based on drug class, the market is categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer's disease market. This is accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment. In addition, the drug is very effective for treating mild to severe dementia, which is contributing to the increasing growth of the segment.

The memantine segment is further expected to be the fastest growing segment during the forecast period. This is ascribed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.

Major players operating in the global dementia and Alzheimer's disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.

Objective of the Study

  • To analyze and estimate the market size of global dementia and Alzheimer's disease treatment market from 2018 to 2021.
  • To estimate and forecast the market size of global dementia and Alzheimer's disease treatment market from 2022 to 2028 and growth rate until 2028.
  • To classify and forecast global dementia and Alzheimer's disease treatment market based on drug class, distribution channel, company and regional distribution.
  • To identify dominant region or segment in the global dementia and Alzheimer's disease treatment market.
  • To identify drivers and challenges for global dementia and Alzheimer's disease treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global dementia and Alzheimer's disease treatment market.
  • To conduct pricing analysis for global dementia and Alzheimer's disease treatment market.
  • To identify and analyze the profile of leading players operating in global dementia and Alzheimer's disease treatment market.
  • to identify key sustainable strategies adopted by market players in global dementia and Alzheimer's disease treatment market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals and presence of all major players across the globe.

TechSci Research calculated the market size of global dementia and Alzheimer's disease treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Dementia and Alzheimer's disease treatment facilities and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to dementia and Alzheimer's disease treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global dementia and Alzheimer's disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Dementia and Alzheimer's Disease Treatment Market, By Drug Class:

  • Cholinergic/ Cholinesterase Inhibitors
    • Donepezil
    • Galantamine
    • Rivastigmine
  • Memantine
  • Combination Drugs
    • Memantine
    • Donepezil
    • Global Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Dementia and Alzheimer's Disease Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global dementia and Alzheimer's disease treatment market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Country
  • 5.8. Clinical Trials Heat Map

6. Global Dementia and Alzheimer's Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors [Donepezil, Galantamine, Rivastigmine], Memantine, Combination Drugs [Memantine & Donepezil]
    • 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
    • 6.2.3. By Company (2022)
    • 6.2.4. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Dementia and Alzheimer's Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Europe Dementia and Alzheimer's Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. North America Dementia and Alzheimer's Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Dementia and Alzheimer's Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Middle East and Africa Dementia and Alzheimer's Disease Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Distribution Channel
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Distribution Channel
    • 11.3.2. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Distribution Channel
    • 11.3.3. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Merz Pharma GmbH & Co. KGaA
  • 14.2. Novartis AG
  • 14.3. Pfizer, Inc.
  • 14.4. Ono Pharmaceutical Co., Ltd.
  • 14.5. Johnson & Johnson Services, Inc.
  • 14.6. H. Lundbeck A/S
  • 14.7. F. Hoffmann-La Roche Ltd.
  • 14.8. AbbVie Inc.
  • 14.9. Eli Lilly and Company
  • 14.10. Corium, Inc.

15. Strategic Recommendations